Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Treace Medical Concepts, Inc. (TMCI), a medical technology firm specializing in bunion treatment, announced that CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat at the Bank of America 2023 Healthcare Conference on May 10, 2023, at 11:40 AM ET. The event will focus on Treace's innovative Lapiplasty® 3D Bunion Correction™ Procedure, aimed at improving surgical outcomes for bunion patients. The company estimates around 1.1 million Americans are annual surgical candidates for bunion correction. A live webcast of the session will be available on Treace's investor relations website.

Treace Medical Concepts (TMCI) announced it will release Q1 2023 financial results on May 8, 2023, after trading ends. The company, which focuses on surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ Procedure, aims to advance standards of care for bunion treatment. Treace estimates around 1.1 million Americans are annual surgical candidates for bunions, affecting approximately 65 million people nationwide. Following the financial results announcement, a conference call will be held at 4:30 PM ET, allowing investors to engage with management. Live and archived webcasts will be accessible through the company’s investor relations website.

Treace Medical Concepts, Inc. (TMCI) has announced significant progress in its intellectual property portfolio, with 15 new patent applications filed and 7 utility patents granted in 2023. The granted patents cover innovative systems and methods for treating bunions, enhancing TMCI's position in the medical technology field. The company's total includes 58 granted patents globally and 84 pending applications, reflecting a commitment to advancing surgical management for bunions. CEO John T. Treace emphasized the importance of these innovations in improving patient care and the protection of proprietary technology.

Treace Medical Concepts (TMCI) announced its fourth quarter and full year 2022 financial results, reporting a 49% increase in revenue for Q4 at $49.8 million, and a 50% increase for 2022 totaling $141.8 million. The gross margin stood at 80.4% for Q4 and 80.6% for the full year. The company also highlighted a strong adoption of the Lapiplasty® procedure, with nearly 1-in-4 U.S. bunion surgeons using it in 2022. Treace granted two new U.S. patents, expanding its portfolio to 40. A follow-on stock offering raised $107.5 million to support growth. The company expects 2023 revenue growth of 32% to 36% year-over-year.

Treace Medical Concepts (TMCI) announced a settlement with Fusion Orthopedics regarding a patent infringement lawsuit filed on March 29, 2022. The litigation, which took place in the U.S. District Court for Arizona, involved claims of patent, trademark, and copyright infringement related to the bunion surgery systems of both companies. While settlement terms remain confidential, Treace Medical is satisfied with the resolution. The company, which focuses on surgical treatments for bunion deformities, emphasizes that approximately 65 million Americans suffer from bunions, with an estimated 1.1 million being surgical candidates annually.

Treace Medical Concepts, Inc. (NASDAQ: TMCI) and Fusion Orthopedics, LLC have resolved their litigation concerning patent and trademark infringement. The lawsuit was initiated on March 29, 2022, when Treace Medical accused Fusion Orthopedics of infringing on its patents related to their respective bunion surgery products. Fusion Orthopedics countered with claims of non-infringement and invalidity. In March 2023, the parties reached a confidential settlement agreement, with Fusion Orthopedics expressing satisfaction with the outcome.

Treace Medical Concepts (NasdaqGS: TMCI) will announce its fourth quarter and full year 2022 financial results on March 7, 2023, following the market close. A conference call will take place at 4:30 pm ET to discuss these results. Treace focuses on surgical treatments for hallux valgus (bunions) through its proprietary Lapiplasty® 3D Bunion Correction™ Procedure. Approximately 65 million Americans are affected by bunions, with an estimated 1.1 million being surgical candidates annually. The company aims to improve surgical management standards for bunion deformities.

Treace Medical Concepts (NasdaqGS: TMCI) announced the latest interim clinical data from its ALIGN3D™ study during the 2023 ACFAS Annual Conference. The study analyzed 128 patients, revealing a remarkable 99.1% maintenance of bunion correction at 24 months and only a 0.9% recurrence rate. Patients experienced an average return to weight-bearing in just 8.1 days, with an 80.8% reduction in pain at 24 months. High satisfaction rates were reported, with 97.3% of patients satisfied at 36 months. Treace also showcased innovations like the Micro-Lapiplasty™ and SpeedPlate™ systems, set for commercialization later this year.